GLP-1 agonists offer added benefits like weight loss and cardiovascular protection, making them ideal for selected patients
Your provider maps a realistic plan first, then gives you a clear figure
The cost gap is real and bigger than most people realize Current 2026 pricing, drawn from live vendor data: Even the compounded route the "supervised" middle tier is 711 more expensive than the research path
This improvement occurs through multiple mechanisms: reduced aromatase activity as fat mass decreases, improved insulin sensitivity, decreased inflammatory cytokines, and restoration of normal hypothalamic-pituitary function
Retatrutide, a triple receptor agonist, targets GLP-1, GIP, and glucagon pathways to influence insulin sensitivity, fat metabolism, and energy regulation
See package insert for complete prescribing information